Gracell Biotechnologies Inc. (GRCL) Misses Q2 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Gracell Biotechnologies Inc. (GRCL) Misses Q2 EPS by 15c

Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update

August 15, 2022 7:16 AM EDT

Presented updated clinical data from an investigator-initiated trial (IIT) evaluating FasTCAR GC012F for the treatment of relapsed/refractory multiple myeloma (r/r MM) at ASCO and EHA 2022, which underscored the deep response with a 100% MRD negativity rate
Presented first-in-human data of GC012F in relapsed/refractory B-cell Non-Hodgkins lymphomas (r/r B-NHL) at EHA 2022Presented updated results from an IIT evaluating allogeneic TruUCAR GC502 in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) at EHA... More